Comments
Drug firm Lupin on Friday said it has received approval from the US health regulator to market generic Colesevelam Hydrochloride tablets used for reducing elevated low-density lipoprotein cholesterol.
The company has received approval to market its Colesevelam Hydrochloride tablet in the strength of 625 mg, from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.
The product is a generic version of Daiichi Sankyo, Inc’s Welchol tablets in the same strength, it added.
According to the IQVIA MAT September 2020 data, Colesevelam Hydrochloride tablets had an annual sales of approximately $159 million in the US market, the filing said.
Colesevelam Hydrochloride tablets, 625 mg, are indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia, it added.
Shares of Lupin Ltd closed at Rs 972.20 per scrip on BSE, up 0.19 per cent over previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.